SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

China-Biotics, Inc – ‘10-K’ for 3/31/12 – ‘R23’

On:  Friday, 9/14/12, at 4:39pm ET   ·   For:  3/31/12   ·   Accession #:  1144204-12-51520   ·   File #:  1-34123

Previous ‘10-K’:  ‘10-K’ on 6/14/10 for 3/31/10   ·   Next:  ‘10-K’ on 5/21/13 for 3/31/11   ·   Latest:  ‘10-K’ on 7/12/13 for 3/31/13

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/14/12  China-Biotics, Inc                10-K        3/31/12   44:3.1M                                   Toppan Merrill/FA

Annual Report   —   Form 10-K   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    747K 
 3: EX-21.1     Subsidiaries List                                   HTML     13K 
 2: EX-16.3     Letter re: Change in Certifying Accountant          HTML     15K 
 4: EX-31.1     Certification -- §302 - SOA'02                      HTML     18K 
 5: EX-31.2     Certification -- §302 - SOA'02                      HTML     18K 
 6: EX-32.1     Certification -- §906 - SOA'02                      HTML     14K 
 7: EX-32.2     Certification -- §906 - SOA'02                      HTML     15K 
27: R1          Document and Entity Information                     HTML     43K 
20: R2          Consolidated Balance Sheets                         HTML    126K 
25: R3          Consolidated Balance Sheets [Parenthetical]         HTML     37K 
29: R4          Consolidated Statements of Operations and Other     HTML    102K 
                Comprehensive Income                                             
40: R5          Consolidated Statements of Changes in               HTML     39K 
                Stockholders' Equity                                             
21: R6          Consolidated Statements of Cash Flows               HTML    128K 
24: R7          Organization and Description of Business            HTML     23K 
19: R8          Summary of Principal Accounting Policies            HTML     57K 
16: R9          Earnings Per Share                                  HTML     28K 
41: R10         Risks, Uncertainties, and Concentrations            HTML     24K 
31: R11         Accounts Receivable                                 HTML     19K 
30: R12         Inventories                                         HTML     19K 
35: R13         Loan Receivable                                     HTML     18K 
36: R14         Deposits                                            HTML     23K 
34: R15         Land Use Right                                      HTML     26K 
37: R16         Property, Plant and Equipment                       HTML     25K 
26: R17         Amount Due to Director                              HTML     17K 
28: R18         Loans Payable                                       HTML     18K 
33: R19         Convertible Notes Payable                           HTML     22K 
44: R20         Income Taxes Payable                                HTML     54K 
38: R21         Treasury Stock                                      HTML     18K 
22: R22         Capital and Statutory Reserves                      HTML     17K 
32: R23         Option Incentive Plan                               HTML     34K 
23: R24         Product Return Concessions                          HTML     18K 
15: R25         Retirement Costs                                    HTML     27K 
39: R26         Commitments and Contingencies                       HTML     38K 
42: R27         Business Segments                                   HTML     38K 
18: R28         Schedule I Condensed Parent Company Financial       HTML     52K 
                Statements                                                       
43: XML         IDEA XML File -- Filing Summary                      XML     55K 
17: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    297K 
 8: EX-101.INS  XBRL Instance -- chbt-20120331                       XML    456K 
10: EX-101.CAL  XBRL Calculations -- chbt-20120331_cal               XML     97K 
11: EX-101.DEF  XBRL Definitions -- chbt-20120331_def                XML    177K 
12: EX-101.LAB  XBRL Labels -- chbt-20120331_lab                     XML    413K 
13: EX-101.PRE  XBRL Presentations -- chbt-20120331_pre              XML    251K 
 9: EX-101.SCH  XBRL Schema -- chbt-20120331                         XSD     69K 
14: ZIP         XBRL Zipped Folder -- 0001144204-12-051520-xbrl      Zip     63K 


‘R23’   —   Option Incentive Plan


This is an IDEA Financial Report.  [ Alternative Formats ]



 
v2.4.0.6
OPTION INCENTIVE PLAN
12 Months Ended
Disclosure Of Compensation Related Costs, Share-Based Payments [Abstract]  
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]
17. OPTION INCENTIVE PLAN

 

On January 16, 2011, the Board adopted the 2010 Equity Incentive Plan (the “2010 Plan”) and reserved 1,500,000 shares of common stock for issuance under the 2010 Plan. On March 9, 2011, the 2010 Plan was approved by the Company’s stockholders at the 2010 Annual Meeting of Stockholders.

 

On January 16, 2011, the Company granted to the directors and officers an option to purchase 910,000 shares of common stock under the 2010 Plan. The options have exercise price of $14.81 per share, an expiration date of five to ten years from the date of grant, and vest over 48 consecutive months: 20% in the first 12-month period; 20% in the second 12-month period; 30% in the third 12-month period; and 30% in the forth 12-month period. The Company determined the fair value of the options on the date of grant was $9,477,024 using the Black-Scholes-Merton option pricing model with the following assumptions: expected volatility, 76%; risk-free interest rate, 1.95%; expected weighted average life, five to ten years; and expected dividend yield, 0%. As of March 31, 2012 and 2011, the total vested options were 165,000 shares and 45,500 shares, respectively.

 

During June 2011, two candidates resigned from their position and terminated their services to the Company. They also did not exercise their vesting options within three months from the date of their termination. According to the option agreement, their options were forfeited and cancelled; the total number of forfeited and cancelled options was 250,000.

 

During the years ended March 31, 2012 and 2011, no vested options were exercised.

 

At March 31, 2012 and 2011, outstanding options were as follows:

 

    Number of
Shares under
Options
    Weighted
Average
Exercise Price
 
             
Options outstanding at April 1, 2010     -     $ -  
Options granted     910,000       14.81  
Options expired or forfeited     -       -  
Options exercised     -       -  
Options outstanding at March 31, 2011     910,000       14.81  
Options granted     -       -  
Options expired or forfeited     (250,000 )     14.81  
Options exercised     -       -  
Options outstanding at March 31, 2012     660,000     $ 14.81  
                 

The following table summarizes information about options outstanding at March 31, 2012:

 

      Options Outstanding     Options Exercisable  
Exercise
price
    Number of
shares
under Option
    Weighted average
remaining contractual life
(years)
    Weighted
Average
Exercise Price
    Number of
shares
under Option
    Weighted
Average
Exercise Price
 
                                             
$ 14.81       660,000       7.15     $ 14.81       165,000     $ 14.81  

 

At March 31, 2012 and 2011, the options outstanding and exercisable had no intrinsic value.

 

For the years ended March 31, 2012 and 2011, the Company has recorded $1,484,690 and $473,852, respectively, as the fair value of the vested options.

 

As of March 31, 2012, total compensation cost related to non-vested stock options and restricted stock not yet recognized was approximately $5,054,193, which is expected to be recognized over the next 33 months


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
Filed on:9/14/12
For Period end:3/31/12NT 10-K
3/31/1110-K,  NT 10-K
3/9/118-K,  DEF 14A
1/16/114,  4/A,  8-K,  8-K/A
4/1/10
9/15/09
 List all Filings 
Top
Filing Submission 0001144204-12-051520   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Mon., Apr. 29, 9:29:31.1am ET